secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2025-12-16T23:59:59+00:00
Accession:  0001193125-25-320009
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar Phase2b REZOLVE-AA: primary endpoint missed; significant after excluding 4 violators. Plans Phase3.
--------------------------------------------------------------------------------

- Mean % SALT reduction at Week 36: 28.2% (24 µg/kg), 30.3% (18 µg/kg) vs 11.2% placebo (p=0.186, p=0.121).
- Excluding 4 patients with major eligibility violations: 29.6%, 30.4% vs 5.7% (p=0.049, p=0.042), meeting significance.
- Key secondary endpoints (SALT30, SALT≤30, SALT≤20, SALT≤10) showed dose-dependent improvement vs placebo.
- Safety well-tolerated; discontinuation rate due to AEs 1.4%, no discontinuations from injection site reactions.
- Plans to present results at a medical conference in 2026; 16-week extension data expected early Q2 2026; advancing to Phase 3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000119312525320009/0001193125-25-320009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000119312525320009/d24251d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-320009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer